PRL
Aliases:
This biomarker is also known as:- PRL
- prolactin
Description…
There is increasing evidence that prolactin (PRL), a hormone/cytokine, plays a role in breast, prostate, and colorectal cancers via local production or accumulation. Elevated levels of serum PRL in ovarian and endometrial cancers have been reported, indicating a potential role for PRL in endometrial and ovarian carcinogenesis.
Datasets
There are no datasets associated with this biomarker.
Attributes
| QA State: | Curated |
|---|---|
| Type: | Protein |
| HGNC Name: | PRL |
The following organs have data associated with this biomarker…
Attributes
| Phase: | 3 |
|---|---|
| QA State: | Under Review |
Organ-specific information for this biomarker is currently being annotated or is "under review".
Logging in may give you privileges to view additional information.
Contact the
Informatics Center
if you believe you should have access to this biomarker.
Attributes
| Phase: | 3 |
|---|---|
| QA State: | Curated |
Organ-specific information for this biomarker is currently being annotated or is "under review".
Logging in may give you privileges to view additional information.
Contact the
Informatics Center
if you believe you should have access to this biomarker.
Attributes
| Phase: | 2 |
|---|---|
| QA State: |
Organ-specific information for this biomarker is currently being annotated or is "under review".
Logging in may give you privileges to view additional information.
Contact the
Informatics Center
if you believe you should have access to this biomarker.
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.
- Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
- Scale-based normalization of spectral data.
- Mining gene expression databases for association rules.
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.